NDRA
ENDRA Life Sciences Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$6.05
+6.51%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +4.0%
- EBIT
- +22.5%
- EPS
- +52.8%
- Free cash flow
- -40.1%
- Operating cash flow
- +13.6%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- -4.9%
- EPS
- +48.8%
Three-year CAGR
- Revenue
- —
- EBITDA
- +39.2%
- EBIT
- +46.7%
- Net income
- +38.9%
- EPS
- +12.9%
- Free cash flow
- +29.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026